---
title: "Ontario TB Presentations Rose During the Pandemic Era but Not After Community SARS-CoV-2 Activity"
id: "medrxiv-10-rising-tuberculosis-presentations-in-ontario-canada-are-not-explained-by"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-10-rising-tuberculosis-presentations-in-ontario-canada-are-not-explained-by"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.14.26367737v1?rss=1"
published_at: "2026-11-17T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Ontario TB Presentations Rose During the Pandemic Era but Not After Community SARS-CoV-2 Activity
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-10-rising-tuberculosis-presentations-in-ontario-canada-are-not-explained-by
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.14.26367737v1?rss=1)
- **Published At:** 2026-11-17T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The investigators performed a population-based ecological time-series study of first acute-care presentations coded for **tuberculosis (TB)** and **nontuberculous mycobacteria (NTM)** in the Greater Toronto/Hamilton Area Plus (GTHA+), Ontario, from April 2011 through March 2024. - Data sources included hospital, emergency-department and ambulatory clinic administrative records capturing first coded presentations; the study used NTM as a comparator because it shares diagnostic pathways with TB but differs epidemiologically. - The team identified 3,985 first TB-coded acute-care presentations and 5,214 first NTM-coded presentations in the study interval. - Negative binomial projection and full-series models estimated pandemic-era changes under three alternative trend assumptions; estimated TB increases across six models ranged from 3% to 22%. - No model suggested an increase in NTM-coded presentations during the pandemic era. - Distributed lag non-linear models assessed associations between standardized community viral activity and subsequent mycobacterial presentations over lags of 0–12 weeks; sensitivity analyses extended maximum lags to 26 and 52 weeks. - For **SARS-CoV-2**, the cumulative rate ratio per 1-SD increase over 0–12 weeks for TB was 0.909 (95% CI 0.822–1.006) and for NTM was 0.953 (0.868–1.047); the study team reported no positive associations. - **Influenza** activity was not associated with TB or NTM presentations in prespecified analyses. - **Respiratory syncytial virus (RSV)** activity was associated with both TB and NTM in time-series models; only the RSV–NTM association met the prespecified Bonferroni threshold among prespecified comparisons. - The authors concluded that community SARS-CoV-2 activity did not temporally explain the modest population-level increase in TB-coded acute-care presentations; they noted that individual-level effects cannot be excluded. - The study used de-identified administrative data under University of Toronto REB approval (Protocol #41690); analysis code and an interactive scenario tool are publicly archived with DOIs provided in the source.
## Clinical Analysis & Structured Key Points
Rising Tuberculosis Presentations in Ontario, Canada Are Not Explained by Community SARS-CoV-2 Activity: A Population-Based Time-Series Study | medRxiv Skip to main content Rising Tuberculosis Presentations in Ontario, Canada Are Not Explained by Community SARS-CoV-2 Activity: A Population-Based Time-Series Study Natalie J. Wilson , View ORCID Profile Ashleigh Tuite , Clara Eunyoung Lee , Rachel J. Berkowitz , Benjamin Wiebe , Jade Hall , Dagmara Boushy , View ORCID Profile David Fisman doi: https://doi.org/10.64898/2026.11.14.26367737 Natalie J. Wilson 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ashleigh Tuite 2 Public Health Agency of Canada Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ashleigh Tuite Clara Eunyoung Lee 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Rachel J. Berkowitz 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Benjamin Wiebe 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jade Hall 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Dagmara Boushy 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site David Fisman 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for David Fisman For correspondence: david.fisman{at}utoronto.ca Abstract Info/History Metrics Data/Code Preview PDF Abstract Background: Tuberculosis (TB) notifications have increased in several high-income countries since 2020. Proposed explanations include pandemic related disruption of treatment for latent tuberculosis, changes in population composition, and immune dysfunction following SARS CoV 2 infection. We assessed whether TB presentations increased during the pandemic era and then tested whether community SARS CoV 2 activity was followed by increased mycobacterial disease. Methods: We conducted a population-based ecological time-series study of first TB- and nontuberculous mycobacterial (NTM)-coded hospital, emergency-department and ambulatory clinic presentations in the Greater Toronto/Hamilton Area Plus (GTHA+), Ontario (2024 population approximately 11.2 million), from April 2011 through March 2024. NTM served as a comparator because it shares diagnostic pathways with TB but differs epidemiologically. Negative binomial projection and full-series models estimated pandemic-era changes under three alternative trend assumptions. Distributed lag non linear models estimated cumulative rate ratios for standardized community viral activity over 0 to 12 weeks; sensitivity analyses extended the maximum lag to 26 and 52 weeks. Influenza and respiratory syncytial virus (RSV) were prespecified comparators; data for five additional viral exposures were obtained after the primary analysis was completed and analysed as exploratory comparisons. Results: We identified 3,985 first TB-coded and 5,214 first NTM-coded acute-care presentations. Across six models, estimated pandemic-era TB increases ranged from 3% to 22%. No model suggested an increased in NTM. SARS-CoV-2 activity was not positively associated with TB (cumulative rate ratio per 1-SD increase over 0 to 12 weeks 0.909, 95% CI 0.822 to 1.006) or NTM (0.953, 0.868 to 1.047). No positive associations were identified in subgroup analyses or with maximum lags of 26 or 52 weeks. Influenza was not associated with either outcome. RSV was associated with TB and NTM; only the RSV/NTM association met the Bonferroni threshold among the prespecified comparisons, and no exploratory associations met the experiment wide threshold. Conclusions: We identified a modest pandemic era increase in TB-coded acute-care presentations in Ontario, Canada, although its estimated size depended on assumptions about underlying trends. NTM-coded presentations did not increase. Community SARS-CoV-2 activity was not positively associated with subsequent TB or NTM presentations at lags of up to one year and did not provide a temporal explanation for the population-level TB increase. Individual-level effects cannot be excluded. Competing Interest Statement DNF has served on advisory boards related to influenza and SARS-CoV-2 vaccines for Seqirus and Pfizer vaccines. ART was employed by the Public Health Agency of Canada when the research was conducted. The work does not represent the views of the Public Health Agency of Canada. Other authors: no competing interests. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study used de-identified administrative data in the CIHI Secure Access Environment and was approved by the Research Ethics Board of the University of Toronto (Protocol # 41690). Applications for access to CIHI data can be completed at https://www.cihi.ca/en/access-data-and-reports/make-a-data-request. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Analysis code is available at DOI: 10.5281/zenodo.22216420. The companion interactive scenario tool runs in any browser at https://fismanda.github.io/mycobacteria-and-respiratory-viruses/ and is archived at DOI: 10.5281/zenodo.22216420. Individual-level administrative health data were accessed within the Canadian Institute for Health Information Secure Access Environment. Respiratory-virus surveillance data are publicly available through the Public Health Agency of Canada. Funder Information Declared Canadian Institutes of Health Research, https://ror.org/01gavpb45 , OV4-170360 , 518192 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted November 17, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Rising Tuberculosis Presentations in Ontario, Canada Are Not Explained by Community SARS-CoV-2 Activity: A Population-Based Time-Series Study Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Rising Tuberculosis Presentations in Ontario, Canada Are Not Explained by Community SARS-CoV-2 Activity: A Population-Based Time-Series Study Natalie J. Wilson , Ashleigh Tuite , Clara Eunyoung Lee , Rachel J. Berkowitz , Benjamin Wiebe , Jade Hall , Dagmara Boushy , David Fisman medRxiv 2026.11.14.26367737; doi: https://doi.org/10.64898/2026.11.14.26367737 Share This Article: Copy Citation Tools Rising Tuberculosis Presentations in Ontario, Canada Are Not Explained by Community SARS-CoV-2 Activity: A Population-Based Time-Series Study Natalie J. Wilson , Ashleigh Tuite , Clara Eunyoung Lee , Rachel J. Berkowitz , Benjamin Wiebe , Jade Hall , Dagmara Boushy , David Fisman medRxiv 2026.11.14.26367737; doi: https://doi.org/10.64898/2026.11.14.26367737 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (642) Allergy and Immunology (925) Anesthesia (355) Cardiovascular Medicine (5041) Dentistry and Oral Medicine (496) Dermatology (431) Emergency Medicine (680) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1702) Epidemiology (16324) Forensic Medicine (36) Gastroenterology (1244) Genetic and Genomic Medicine (7312) Geriatric Medicine (758) Health Economics (1099) Health Informatics (5325) Health Policy (1479) Health Systems and Quality Improvement (1842) Hematology (600) HIV/AIDS (1386) Infectious Diseases (except HIV/AIDS) (16518) Intensive Care and Critical Care Medicine (1206) Medical Education (702) Medical Ethics (157) Nephrology (755) Neurology (7642) Nursing (380) Nutrition (1138) Obstetrics and Gynecology (1301) Occupational and Environmental Health (1045) Oncology (3756) Ophthalmology (1101) Orthopedics (413) Otolaryngology (470) Pain Medicine (506) Palliative Medicine (144) Pathology (722) Pediatrics (1871) Pharmacology and Therapeutics (758) Primary Care Research (789) Psychiatry and Clinical Psychology (6169) Public and Global Health (10034) Radiology and Imaging (2550) Rehabilitation Medicine and Physical Therapy (1533) Respiratory Medicine (1277) Rheumatology (663) Sexual and Reproductive Health (811) Sports Medicine (601) Surgery (807) Toxicology (109) Transplantation (320) Urology (309)
## Related Clinical Research

- [Burden of RSV Hospitalizations in Brazilian Adults Aged ≥60 Years (2013–2024)](https://medichelpline.com/clinical-feed/pubmed-42758792.md) (DOI: 10.1371/journal.pone.0357303)
- [CXR and Bandim TBScore Weakly Predict Two‑Month Culture Conversion in PTB](https://medichelpline.com/clinical-feed/medrxiv-7-tuberculosis-severity-metrics-poorly-predict-two-month-culture-conversion.md)
- [Impact of loss to follow-up on 5-year mortality after tuberculosis treatment in São Paulo, Brazil](https://medichelpline.com/clinical-feed/plos-medicine-0-loss-to-follow-up-during-tuberculosis-treatment-and-5-year-mortality-in-brazil.md)
- [SARS-CoV-2 antibody landscape after multiple Omicron-era vaccinations and infections](https://medichelpline.com/clinical-feed/medrxiv-23-sars-cov-2-antibody-landscape-following-multiple-vaccinations-and-infections.md)
- [Distinct Maturation-Associated Neutrophil Transcriptional Programs in COVID-19 Versus Tuberculosis](https://medichelpline.com/clinical-feed/biorxiv-2-covid-19-and-active-tuberculosis-exhibit-distinct-maturation-associated.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.